Medtronic Tandem Diabetes CareTwo major insulin pump makers — Medtronic (NYSE:MDT) and Tandem Diabetes Care (NSDQ:TNDM) — announced today that they’ve inked a non-exclusive patent cross-license agreement related to diabetes treatment tech.

The companies said the agreement will allow them to focus on innovation while avoiding the distraction of potential legal disagreements.

The deal could be but another example of how medical device companies are trying to avoid unnecessary costs — including potentially money-draining litigation and IP cases — amid the COVID-19 pandemic and resulting recession.

Get the full story on our sister site Drug Delivery Business News.